Efficacy and safety of the B-domain-deleted TQG202 for on-demand treatment in moderate and severe haemophilia A patients: A multicentre, single-arm trial.

Zimin SunYaming XiXiaohong Sun Lin-Hua YangXuefeng WangChenghao JinHaifei JiaLei Zhang

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)

TQG202 for on-demand treatment in moderate/severe haemophilia A shows effective control of the bleeding symptoms, with a low incidence of adverse events and inhibitors development.

Keyphrases

end stage renal disease
clinical trial
study protocol
ejection fraction
chronic kidney disease
high intensity
randomized controlled trial
risk factors
depressive symptoms
physical activity
smoking cessation